Monoclonal antibodies have become a mainstay in the treatment of patients with relapsing
multiple sclerosis (RMS) and provide some benefit to patients with primary progressive MS …

Multiple sclerosis (MS) is an inflammatory and degenerative disease leading to
demyelination and axonal damage in the CNS. Autoimmunity plays a central role in MS …

Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in
medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant …

Background: Monoclonal antibodies constitute a relatively new class of therapeutic agent
designed to interact with specific target antigens. Monoclonal antibodies can be created to …

Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted
approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was …

The global incidence of multiple sclerosis (MS) appears to be increasing. Although it may
not be associated with a high mortality rate, this disease has a high morbidity rate which …

Monoclonal antibody (mAb) therapies for relapsing-remitting multiple sclerosis (MS) target
immune cells or other molecules involved in pathogenic pathways with extraordinary …

Therapeutic approaches to multiple sclerosis (MS) are based on altering the functions of the
immune system, either by using broad immunosuppressive drugs used for transplantation …

The use of monoclonal antibodies in multiple sclerosis (MS) patients is in a transitional
period. Studies regarding well-established, effective antibodies such as natalizumab and …

The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with
monoclonal antibodies covers the years 2010–2012. The natalizumab section gives a …